Abstract
Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.
and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF
Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 977-983 |
| Number of pages | 7 |
| Journal | European Journal of Heart Failure |
| Volume | 16 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Baroreflex
- Heart failure
- Non-pharmacological therapy
- Sympathetic nervous system
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure : A proof-of-concept study. / Gronda, Edoardo; Seravalle, Gino; Brambilla, Gianmaria; Costantino, Giuseppe; Casini, Andrea; Alsheraei, Ali; Lovett, Eric G.; Mancia, Giuseppe; Grassi, Guido.
In: European Journal of Heart Failure, Vol. 16, No. 9, 2014, p. 977-983.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure
T2 - A proof-of-concept study
AU - Gronda, Edoardo
AU - Seravalle, Gino
AU - Brambilla, Gianmaria
AU - Costantino, Giuseppe
AU - Casini, Andrea
AU - Alsheraei, Ali
AU - Lovett, Eric G.
AU - Mancia, Giuseppe
AU - Grassi, Guido
PY - 2014
Y1 - 2014
N2 - Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.
AB - Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.
KW - Baroreflex
KW - Heart failure
KW - Non-pharmacological therapy
KW - Sympathetic nervous system
UR - http://www.scopus.com/inward/record.url?scp=84908242972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908242972&partnerID=8YFLogxK
U2 - 10.1002/ejhf.138
DO - 10.1002/ejhf.138
M3 - Article
C2 - 25067799
AN - SCOPUS:84908242972
VL - 16
SP - 977
EP - 983
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 9
ER -